The Rift Valley fever accessory proteins NSm and P78/NSm-G N are distinct determinants of virus propagation in vertebrate and invertebrate hosts

Emerging Microbes and Infections

Volumn 3, Issue , 2014, Pages

  Kreher, Felix ^a,b   Tamietti, Carole ^a,b   Gommet, Céline ^a,c   Guillemot, Laurent ^a   Ermonval, Myriam ^a   Failloux, Anna Bella ^a   Panthier, Jean Jacques ^a   Bouloy, Michèle ^a   Flamand, Marie ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c DIF   (France)

Author keywords

arbovirus; attenuation; bunyavirus; minor structural protein; non structural protein; transmission; vector; virulence factor

Indexed keywords

PROTEIN NSM GN; PROTEIN P78; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

3' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; CODON; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MACROPHAGE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; STOP CODON; VIRUS VIRULENCE;

ARBOVIRUS; ARTHROPODA; INVERTEBRATA; MAMMALIA; MURINAE; MUS; ORTHOBUNYAVIRUS; RIFT VALLEY FEVER VIRUS; VERTEBRATA;

EID: 84923332105     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.69     Document Type: Article

References (55)

1. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or rift valley fever. An undescribed virus disease of sheep cattle and man from east africa. J Pathol Bacteriol 1931; 34: 545-579.
2. Findlay GM. Rift valley fever or enzootic hepatitis. Trans R Soc Trop Med Hyg 1932; 25: 229-IN211.
3. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. Rift Valley fever virus. J Am Vet Med Assoc 2009; 234: 883-893.
4. Meegan JM, Hoogstraal H, Moussa MI. An epizootic of Rift Valley fever in Egypt in 1977. Vet Rec 1979; 105: 124-125.
5. Arthur RR, El-Sharkawy MS, Cope SE et al. Recurrence of Rift Valley fever in Egypt. Lancet 1993; 342: 1149-1150.
6. Chevalier V, Pepin M, Plee L, Lancelot R. Rift Valley fever - a threat for Europe? Euro Surveill 2010; 15: 19506.
7. Gale P, Brouwer A, Ramnial V et al. Assessing the impact of climate change on vectorborne viruses in the EU through the elicitation of expert opinion. Epidemiol Infect 2009; 138: 214-225.
8. Hoogstraal H, Meegan JM, Khalil GM, Adham FK. The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies. Trans R Soc Trop Med Hyg 1979; 73: 624-629.
9. Madani TA, Al-Mazrou YY, Al-Jeffri MH et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003; 37: 1084-1092.
10. Mohamed M, Mosha F, Mghamba J et al. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am J Trop Med Hyg 2010; 83: 22-27.
11. PepinM, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 2010; 41: 61.
12. Laughlin LW, Meegan JM, Strausbaugh LJ, Morens DM, Watten RH. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg 1979; 73: 630-633.
13. Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses 2011; 3: 493- 519.
14. Plyusnin A, Elliott RM. Bunyaviridae: molecular and cellular biology. Norfolk: Caister Academic Press, 2011.
15. Ikegami T. Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res 2012; 95: 293-310.
16. Schmaljohn CS, Nichol ST. Bunyaviridae. In: Knipe DM, Howley PM (ed.) Fields virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2007: 1741- 1789.
17. Kakach LT, Wasmoen TL, Collett MS. Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J Virol 1988; 62: 826-833.
18. Suzich JA, Collett MS. Rift Valley fever virus M segment: cell-free transcription and translation of virus-complementary RNA. Virology 1988; 164: 478-486.
19. Suzich JA, Kakach LT, Collett MS. Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment. J Virol 1990; 64: 1549- 1555.
20. Wasmoen TL, Kakach LT, Collett MS. Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins. Virology 1988; 166: 275-280.
21. Gerrard SR, Nichol ST. Synthesis, proteolytic processing and complex formation of Nterminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 2007; 357: 124-133.
22. Kortekaas J, Oreshkova N, Cobos-Jiménez V et al. Creation of a nonspreading Rift Valley fever virus. J Virol 2011; 85: 12622-12630.
23. Pichlmair A, Habjan M, Unger H, Weber F. Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus. Vector Borne Zoonotic Dis 2010; 10: 701-703.
24. Struthers JK, Swanepoel R, Shepherd SP. Protein synthesis in Rift Valley fever virusinfected cells. Virology 1984; 134: 118-124.
25. Weingartl HM, Zhang SZ, Marszal P, McGreevy A, Burton L, Wilson WC. Rift Valley Fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells. PLoS ONE 2014; 9: e87385.
26. Won S, Ikegami T, Peters CJ, Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007; 81: 13335-13345.
27. Gerrard SR, Bird BH, Albarino CG, Nichol ST. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 2007; 359: 459-465.
28. Won S, Ikegami T, Peters CJ, Makino S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J Virol 2006; 80: 8274- 8278.
29. Bird BH, Albarino CG, Nichol ST. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007; 362: 10-15.
30. Crabtree MB, Kent Crockett RJ, BirdBH et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Negl Trop Dis 2012; 6: e1639.
31. Kading RC, Crabtree MB, Bird BH et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl Trop Dis 2014; 8: e2670.
32. Ito N, Takayama-Ito M, Yamada K, Hosokawa J, Sugiyama M, Minamoto N. Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol Immunol 2003; 47: 613-617.
33. Billecocq A, Gauliard N, Le May N, Elliott RM, Flick R, Bouloy M. RNA polymerase Imediated expression of viralRNAfor the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 2008; 378: 377-384.
34. do Valle TZ, Billecocq A, Guillemot L et al. A new mouse model reveals a critical role for host innate immunity in resistance to Rift Valley fever. J Immunol 2010; 185: 6146- 6156.
35. Terasaki K, Won S, Makino S. The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts antiapoptotic function. J Virol 2013; 87: 676-682.
36. Ross TM, Bhardwaj N, Bissel SJ, Hartman AL, Smith DR. Animal models of Rift Valley fever virus infection. Virus Res 2012; 163: 417-423.
37. Gommet C, Billecocq A, Jouvion G et al. Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice. PLoS Negl Trop Dis 2011; 5: e1421.
38. Moutailler S, Krida G, Schaffner F, Vazeille M, Failloux AB. Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonotic Dis 2008; 8: 749-753.
39. Smith DR. Steele KE, Shamblin J et al. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 2010; 407: 256-267.
40. Kamal SA. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 2009; 6: 94.
41. McElroy AK, Nichol ST. Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 2011; 422: 6-12.
42. Reed C, Steele KE, Honko A, Shamblin J, Hensley LE, Smith DR. Ultrastructural study of Rift Valley fever virus in the mouse model. Virology 2012; 431: 58-70.
43. Shieh WJ, Paddock CD, Lederman E et al. Pathologic studies on suspect animal and human cases of Rift Valley fever from an outbreak in Eastern Africa, 2006-2007.AmJ Trop Med Hyg 2010; 83: 38-42.
44. Narayanan A, Popova T, Turell M et al. Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection. PLoS ONE 2011; 6: e20354.
45. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1.
46. Engdahl C, Naslund J, Lindgren L, Ahlm C, Bucht G. The Rift Valley Fever virus protein NSm and putative cellular protein interactions. Virol J 2012; 9: 139.
47. Wang T, Campbell RV, Yi MK, Lemon SM, Weinman SA. Role of hepatitis C virus core protein in viral-induced mitochondrial dysfunction. J Viral Hepat 2010; 17: 784-793.
48. Okuda M, Li K, BeardMR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375.
49. Waris G, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol Cell Biol 2001; 21: 7721-7730.
50. Ellis DS, Shirodaria PV, Fleming E, Simpson DI. Morphology and development of Rift Valley fever virus in Vero cell cultures. J Med Virol 1988; 24: 161-174.
51. Kakach LT, Suzich JA, Collett MS. Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology 1989; 170: 505-510.
52. Cavener DR. Comparison of the consensus sequence flanking translational start sites in Drosophila and vertebrates. Nucleic Acids Res 1987; 15: 1353-1361.
53. Firth AE, Brierley I. Non-canonical translation in RNA viruses. J Gen Virol 2012; 93: 1385-1409.
54. Greene IP, Wang E, Deardorff ER, Milleron R, Domingo E, Weaver SC. Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. J Virol 2005; 79: 14253-14260.
55. Moutailler S, Roche B, Thiberge JM, Caro V, Rougeon F, Failloux AB. Host alternation is necessary to maintain the genome stability of rift valley fever virus. PLoS Negl Trop Dis 2011; 5: e1156.